menu

CME: Clinical Considerations in Treatment Sequencing for mCRC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Clinical Considerations in Treatment Sequencing for mCRC

Program Information
Recommended
Clinical Considerations in Treatment Sequencing for mCRC
RestartResume
What do you need to think about when selecting chemotherapy and biologic combinations in the treatment of patients with mCRC?

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Selecting optimal therapy for patients with mCRC after first-line failure can often best be informed by identifying the current driver oncogenes specific to each individual’s cancer. Such an approach can provide a more nuanced selection of chemotherapy (CT) and biologic combinations in second- and subsequent lines, including guidance for switching or continuing with a particular CT or biologic agent.

    So how can you implement this approach in your practice? Dr. Alfredo Falcone is joined by Drs. Sebastian Stintzing and Tianshu Liu to share insights.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Alfredo Falcone, MD                                                       
    Professor of Medical Oncology
    Chief Division of Oncology
    University of Pisa
    Pisa, Italy

    Dr. Falcone has disclosed he receives consulting fees from Amgen, Bayer, Bristol Myers Squibb, Eli Lilly and Company, Merck, Roche, Servier, and does contracted research for Amgen, Bayer, Merck, Roche, and Servier.

    Tianshu Liu, MD
    Director, Dept of Medical Oncology
    Shanghai Zhong Shan Hospital
    Fudan University
    Shanghai, China

    Dr. Liu has nothing has nothing to disclose.

    Sebastian Stintzing, MD
    Head of Department
    Medical Department, Division of Oncology and Hematology
    Charité Universitätsmedizin Berlin
    Berlin, Germany

    Dr. Stintzing has disclosed he receives consulting fees and is a member of the speaker bureau for Amgen, Bayer, Eli Lilly and Company, Merck, Roche, Samsung, Sanofi, Siries, Taiho, and Takeda.

    Reviewers/Content Planners/Authors:

    • Sean Barrett has nothing to disclose.
    • Rob Braun has nothing to disclose.
    • Ann Early has nothing to disclose.  
    • Barry Fiedel, PhD has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Formulate treatment strategies based on a patient’s tumor characteristics, including the role of repeat genetic testing, therapy rechallenge, and combination therapy to improve outcomes and survival.
    2. Evaluate approaches to assess mechanisms of treatment resistance, and the role of monitoring for resistance to assist in optimizing clinical decision-making.
  • Target Audience

    This activity is designed to meet the educational needs of Oncologists, Oncology Nurses, and Pathologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider(s)/Educational Partner(s)

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients with colorectal cancer. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Programs 9/19/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.